Evidence map›Paper›PMID 36472908›Full record

ArticleJCI insight2023

Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune circuits related to tissue injury.

Amy R Cross, Carlos E de Andrea, María Villalba-Esparza, Manuel F Landecho, Lucia Cerundolo, Praveen Weeratunga, Rachel E Etherington, Laura Denney, Graham Ogg, Ling-Pei Ho and 6 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 30 citations in OpenAlex.

  1. Insights Into Spatial Transcriptomics: Exploring Recent Technical Developments and Their Diverse Applications.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Multi-omics to study chronic respiratory diseases and viral infections.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Amy R CrossNuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
Carlos E de AndreaDepartment of Pathology.
María Villalba-EsparzaDepartment of Pathology.
Manuel F LandechoDepartment of Internal Medicine, and.
Lucia CerundoloNuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
Praveen WeeratungaMedical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Rachel E EtheringtonMedical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Laura DenneyMedical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Graham OggMedical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Ling-Pei HoMedical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Ian Sd RobertsDepartment of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Joanna HesterNuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
Paul KlenermanNuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Ignacio MeleroDepartment of Immunology and Immunotherapy, Clínica de la Universidad de Navarra, Pamplona, Spain.
Stephen N SansomKennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom.
Fadi IssaNuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom.
University of Oxford · GBMRC Human Immunology Unit · GBClinica Universidad de Navarra · ESOxford University Hospitals NHS Trust · GB

Funding

Medical Research Council MC_PC_17174Medical Research Council MC_PC_18059Medical Research Council MC_PC_20002Medical Research Council MC_UU_00008/5Medical Research Council MC_UU_00036/2Medical Research Council MR/N027930/1Medical Research Council MR/S020918/1Wellcome Trust
6 · The paper itself

Abstract

Severe lung damage resulting from COVID-19 involves complex interactions between diverse populations of immune and stromal cells. In this study, we used a spatial transcriptomics approach to delineate the cells, pathways, and genes present across the spectrum of histopathological damage in COVID-19-affected lung tissue. We applied correlation network-based approaches to deconvolve gene expression data from 46 areas of interest covering more than 62,000 cells within well-preserved lung samples from 3 patients. Despite substantial interpatient heterogeneity, we discovered evidence for a common immune-cell signaling circuit in areas of severe tissue that involves crosstalk between cytotoxic lymphocytes and pro-inflammatory macrophages. Expression of IFNG by cytotoxic lymphocytes was associated with induction of chemokines, including CXCL9, CXCL10, and CXCL11, which are known to promote the recruitment of CXCR3+ immune cells. The TNF superfamily members BAFF (TNFSF13B) and TRAIL (TNFSF10) were consistently upregulated in the areas with severe tissue damage. We used published spatial and single-cell SARS-CoV-2 data sets to validate our findings in the lung tissue from additional cohorts of patients with COVID-19. The resulting model of severe COVID-19 immune-mediated tissue pathology may inform future therapeutic strategies.

Indexed as

COVID-19PneumoniaHumansLungSARS-CoV-2TranscriptomeCellular immune responseChemokinesCOVID-19InflammationMolecular pathology

Identifiers

PMID36472908
PMCPMC9977306
OpenAlexW4310785558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.